Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Progyny (PGNY) Gains from Sales and Divestitures (2020 - 2021)

Progyny (PGNY) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $201916.0 as the latest value for Q4 2021.

Quarterly Gains from Sales and Divestitures rose 319.82% to $201916.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $201916.0 through Dec 2021, up 319.82% year-over-year, with the annual reading at $201916.0 for FY2021, 319.82% up from the prior year.
Gains from Sales and Divestitures for Q4 2021 was $201916.0 at Progyny, up from $48096.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $201916.0 in Q4 2021, with the low at $48096.0 in Q4 2020.